	US RE50,453 E1
	Indole derivatives as CFTR modulators
Sara S. Hadida Ruah, La Jolla, CA (US); Peter D. J. Grootenhuis, San Diego, CA (US); Fredrick Van Goor, San Diego, CA (US); Jinglan Zhou, San Diego, CA (US); Brian Bear, Oceanside, CA (US); Mark T. Miller, San Diego, CA (US); Jason McCartney, Cardiff by the Sea, CA (US); Mehdi Michel Djamel Numa, San Diego, CA (US); and Xiaoqing Yang, San Diego, CA (US)
Assigned to Vertex Pharmaceuticals Incorporated, Boston, MA (US)
Filed by Vertex Pharmaceuticals Incorporated, Boston, MA (US)
Filed on Dec. 28, 2022, as Appl. No. 18/089,898.
Application 18/089,898 is a continuation in part of application No. 11/786,001, filed on Apr. 9, 2007, granted, now 7,776,905, issued on Aug. 17, 2010.
Application 18/089,898 is a reissue of application No. 11/975,297, filed on Oct. 18, 2007, granted, now 7,645,789, issued on Jan. 12, 2010.
Claims priority of provisional application 60/790,459, filed on Apr. 7, 2006.
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/404 (2006.01); A61K 31/4045 (2006.01); A61K 31/405 (2006.01); A61K 31/407 (2006.01); A61K 31/41 (2006.01); A61K 31/4184 (2006.01); A61K 31/4192 (2006.01); A61K 31/454 (2006.01); A61K 31/47 (2006.01); A61K 31/5377 (2006.01); A61K 45/06 (2006.01); C07D 209/08 (2006.01); C07D 233/64 (2006.01); C07D 403/12 (2006.01); C07D 405/12 (2006.01); C07D 405/14 (2006.01); C07D 471/04 (2006.01); C07D 487/04 (2006.01); G01N 33/50 (2006.01)

CPC A61K 31/47 (2013.01) [A61K 31/404 (2013.01); A61K 31/4045 (2013.01); A61K 31/405 (2013.01); A61K 31/407 (2013.01); A61K 31/41 (2013.01); A61K 31/4184 (2013.01); A61K 31/4192 (2013.01); A61K 31/454 (2013.01); A61K 31/5377 (2013.01); A61K 45/06 (2013.01); C07D 209/08 (2013.01); C07D 233/64 (2013.01); C07D 403/12 (2013.01); C07D 405/12 (2013.01); C07D 405/14 (2013.01); C07D 471/04 (2013.01); C07D 487/04 (2013.01); G01N 33/5035 (2013.01); G01N 2333/705 (2013.01); G01N 2500/10 (2013.01)]

3 Claims

1. A compound of formula:

or a pharmaceutically acceptable salt thereof.